SEARCH

SEARCH BY CITATION

References

  • 1
    Dignan, F. L., Amrolia, P., Clark, A., Cornish, J., Jackson, G., Mahendra, P., Scarisbrick, J. J. et al., Diagnosis and management of chronic graft-versus-host disease. Br. J. Haematol. 2012. 158: 4661.
  • 2
    Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C. et al., Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011. 117: 46514657.
  • 3
    Wolf, D., von Lilienfeld-Toal, M., Wolf, A. M., Schleuning, M., von Bergwelt-Baildon, M., Held, S. A. E. and Brossart, P., Novel treatment concepts for graft-versus-host disease. Blood 2012. 119: 1625.
  • 4
    Coghill, J. M., Sarantopoulos, S., Moran, T. P., Murphy, W. J., Blazar, B. R. and Serody, J. S., Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011. 117: 32683276.
  • 5
    Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009. 27: 485517.
  • 6
    Yi, T., Zhao, D., Lin, C. L., Zhang, C., Chen, Y., Todorov, I., LeBon, T. et al., Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008. 112: 21012110.
  • 7
    Dander, E., Balduzzi, A., Zappa, G., Lucchini, G., Perseghin, P., Andre, V., Todisco, E. et al., Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009. 88: 12611272.
  • 8
    Zhao, X. Y., Xu, L. L., Lu, S. Y. and Huang, X. J., IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur. J. Immunol. 2011. 41: 514526.
  • 9
    Nishimori, H., Maeda, Y., Teshima, T., Sugiyama, H., Kobayashi, K., Yamasuji, Y., Kadohisa, S. et al., Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood 2012. 119: 285295.
  • 10
    Chen, X., Das, R., Komorowski, R., van Snick, J., Uyttenhove, C. and Drobyski, W. R., Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. Biol. Blood Marrow Transpl. 2010. 16: 123128.
  • 11
    Ratajczak, P., Janin, A., Peffault de Latour, R., Leboeuf, C., Desveaux, A., Keyvanfar, K., Robin, M. et al., Th17/Treg ratio in human graft-versus-host disease. Blood 2010. 116: 11651171.
  • 12
    Korn, T., Bettelli, E., Gao, W., Awasthi, A., Jager, A., Strom, T. B., Oukka, M. et al., IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007. 448: 484487.
  • 13
    Meguro, A., Ozaki, K., Oh, I., Hatanaka, K., Matsu, H., Tatara, R., Sato, K. et al., IL-21 is critical for GVHD in a mouse model. Bone Marrow Transpl. 2010. 45: 723729.
  • 14
    Bucher, C., Koch, L., Vogtenhuber, C., Goren, E., Munger, M., Panoskaltsis-Mortari, A., Sivakumar, P. et al., IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009. 114: 53755384.
  • 15
    Hippen, K. L., Bucher, C., Schirm, D. K., Bearl, A. M., Brender, T., Mink, K. A., Waggie, K. S. et al., Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2012. 119: 619628.
  • 16
    Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R. et al., Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am. J. Med. 1980. 69: 204217.
  • 17
    Schmittgen, T. D. and Livak, K. J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008. 3: 11011108.
  • 18
    Filipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P. et al., National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transpl. 2005. 11: 945956.
  • 19
    Serody, J. S. and Hill, G. R., The IL-17 differentiation pathway and its role in transplant outcome. Biol. Blood Marrow Transpl. 2012. 18: S56S61.
  • 20
    Litjens, N. H., van de Wetering, J., van Besouw, N. M. and Betjes, M. G., The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches. Blood 2009. 114: 39473955.
  • 21
    Wilke, C. M., Bishop, K., Fox, D. and Zou, W., Deciphering the role of Th17 cells in human disease. Trends Immunol. 2011. 32: 603611.
  • 22
    Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006. 441: 235238.
  • 23
    Huang, X.-J., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Chen, H. and Han, W., Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007. 92: 414417.
  • 24
    Wang, Y., Liu, D. H., Xu, L. P., Liu, K. Y., Chen, H., Zhang, X. H., Chen, Y. H. et al., Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transpl. 2011. 47: 10991104.
  • 25
    Yan, C. H., Liu, D. H., Xu, L. P., Liu, K. Y., Zhao, T., Wang, Y., Chen, H. et al., Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin. Transplant. 2012. 26: 868876.
  • 26
    Jun, H. X., Jun, C. Y. and Yu, Z. X., A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF) primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005. 90: 715716.
  • 27
    Jun, H. X., Jun, C. Y. and Yu, Z. X., In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004. 89: 15171524.
  • 28
    Chang, Y. J., Zhao, X. Y., Huo, M. R. and Huang, X. J., Expression profiles of adhesion molecules on naive T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl. Immunol. 2009. 21: 228233.
  • 29
    Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J. et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000. 408: 5763.
  • 30
    Nurieva, R., Yang, X. O., Martinez, G., Zhang, Y., Panopoulos, A. D., Ma, L., Schluns, K. et al., Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007. 448: 480483.
  • 31
    Monteleone, G., Pallone, F. and MacDonald, T. T., Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol. 2008. 29: 290294.
  • 32
    Weisdorf, D., Zhang, M. J., Arora, M., Horowitz, M. M., Rizzo, J. D. and Eapen, M., Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol. Blood Marrow Transpl. 2012. 18: 17271733.
  • 33
    Baron, F., Labopin, M., Niederwieser, D., Vigouroux, S., Cornelissen, J. J., Malm, C., Vindelov, L. L. et al., Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012. 26: 24622468.
  • 34
    Rangarajan, H., Yassai, M., Subramanian, H., Komorowski, R., Whitaker, M., Gorski, J. and Drobyski, W. R., Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. Blood 2012. 119: 63546364.
  • 35
    Carlens, S., Ringden, O., Remberger, M., Lonnqvist, B., Hagglund, H., Klaesson, S., Mattsson, J. et al., Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl. 1998. 22: 755761.
  • 36
    Martires, K. J., Baird, K., Steinberg, S. M., Grkovic, L., Joe, G. O., Williams, K. M., Mitchell, S. A. et al., Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011. 118: 42504257.
  • 37
    Huang, X. J., Liu, D. H., Liu, K. Y., Xu, L. P., Chen, H., Han, W., Chen, Y. H. et al., Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transpl. 2006. 38: 291297.
  • 38
    Lu, D. P., Dong, L., Wu, T., Huang, X. J., Zhang, M. J., Han, W., Chen, H. et al., Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006. 107: 30653073.
  • 39
    Huang, X. J., Zhu, H. H., Chang, Y. J., Xu, L. P., Liu, D. H., Zhang, X. H., Jiang, B. et al., The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012. 119: 55845590.
  • 40
    Jiang, Q., Xu, L. P., Liu, D. H., Liu, K. Y., Chen, S. S., Jiang, B., Jiang, H. et al., Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011. 117: 30323040.
  • 41
    Zhao, X. S., Jin, S., Zhu, H. H., Xu, L. P., Liu, D. H., Chen, H., Liu, K. Y. et al., Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transpl. 2012. 47: 499507.
  • 42
    Zhao, X. S., Liu, Y. R., Zhu, H. H., Xu, L. P., Liu, D. H., Liu, K. Y. and Huang, X. J., Monitoring MRD with flow cytometry: an effective method to predict relapse for all patients after allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 2012. 91: 183192.
  • 43
    Yan, C. H., Liu, D. H., Liu, K. Y., Xu, L. P., Liu, Y. R., Chen, H., Han, W. et al., Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012. 119: 32563262.
  • 44
    Wang, Y., Liu, D. H., Fan, Z. P., Sun, J., Wu, X. J., Ma, X., Xu, L. P. et al., Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin. Transpl. 2012. 26: 635643.
  • 45
    Thomas, E. D., Storb, R., Clift, R. A., Fefer, A., Johnson, L., Neiman, P. E., Lerner, K. G. et al., Bone-marrow transplantation (second of two parts). N. Engl. J. Med. 1975. 292: 895902.